Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TET3 | O43151 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | FBXL19 | Q6PCT2 | 2/20 | 0.33 |
| ▸ | CXXC5 | Q7LFL8 | 2/20 | 0.33 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.33 |
| ▸ | CXXC4 | Q9H2H0 | 2/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.33 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22440476 | 0.80 | OPRM1 (0.32) | — | |
| SCHEMBL5767608 | 0.78 | — | — | |
| SCHEMBL9254411 | 0.72 | MEN1 (0.33) | KMT2A | |
| SCHEMBL10818983 | 0.71 | MEN1 (0.35) | KMT2A | |
| SCHEMBL29281624 | 0.71 | MEN1 (0.35) | KMT2A | |
| SCHEMBL21359816 | 0.71 | KMT2A (0.33) | KMT2A | |
| SCHEMBL10817404 | 0.70 | MEN1 (0.38) | KMT2A | |
| SCHEMBL17763731 | 0.69 | TET3 (0.30) | TET3KMT2AFBXL19CXXC5KDM2B | |
| SCHEMBL1847022 | 0.69 | CRBN (0.34) | — | |
| SCHEMBL18446067 | 0.68 | TET3 (0.32) | TET3KMT2AFBXL19CXXC5KDM2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105507-B2 | Cyclohexane derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LIMITED (GB) | 2006-09-12 | — | — | US | disclosed |
| US-20030236250-A1 | Cyclohexane derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LTD. (GB) | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236250-A1 | Cyclohexane derivatives and their use as therapeutic agents | CNR2, CNR1, HTR1A | TET3 4276/4885KMT2A 2954/4885FBXL19 2557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.